US Stock MarketDetailed Quotes
ASLN Aslan Pharmaceuticals
- 0.6000
- 0.00000.00%
Trading Jul 18 16:00 ET
1.70MMarket Cap-38P/E (TTM)
0.0000High0.0000Low0Volume0.0000Open0.6000Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)2.83MShares19.399252wk High-0.09P/B1.49MFloat Cap0.475052wk Low--Dividend TTM2.49MShs Float417.5600Historical High--Div YieldTTM0.00%Amplitude0.4750Historical Low--Avg Price1Lot Size
About Aslan Pharmaceuticals Company
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The Company’s major business is research and development and operates only in one single segment.
Company Profile
SymbolASLN
Company NameAslan Pharmaceuticals
Issue Price7.03
CEODr. Carl Firth, PhD
MarketNASDAQ
Employees35
Securities TypeDR
ADS Ratio1.0 : 200.0
Fiscal Year Ends12-31
Websitehttps://aslanpharma.com
Company Executives
- Name
- Position
- Salary
- Dr. Carl Firth, PhD
- Director and Chief Executive Officer
- --
- Kiran Asarpota
- Chief Operating Officer and Head of Finance
- --
- Dr. Alexandre Kaoukhov, M.D.
- Chief Medical Officer
- --
- Stephen Doyle
- Chief Business Officer
- --
- Andrew Howden
- Chairman of the Board
- 92.38K
- Dr. Neil Graham, M.B.B.S.,M.D.,M.P.H.
- Independent Director
- 66.29K
- Robert E. Hoffman, C.P.A.
- Independent Director
- 63.25K
- Dr. Kathleen M. Metters, PhD
- Independent Director
- 58.50K
- Ben Goodger
- General Counsel
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg